RxDoctor Payments Data

Heidi Crayton, MD

Neurology · Vienna, VANPI 1669470720

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,007,357 of the $1,471,894 with a category attached, or 68.4%. 43 manufacturers reported payments, led by EMD Serono, Inc. at 30.9% of the total. Among neurology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,471,894in general payments, 2019–2025

Across 2,484 payments — averaging $592.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$455K
  • Biogen$357K
  • Sanofi$242K
  • E.r. Squibb & Sons, L.L.C.$114K
  • Bristol Myers Squibb$70K
  • TG Therapeutics, Inc.$47K
  • plus $186K from 37 others
$1,060,884in research payments, 2019–2025

Across 220 payments — averaging $4822.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$466K
  • Sanofi$206K
  • Biogen$187K
  • TG Therapeutics, Inc.$80K
  • Genentech, Inc.$63K
  • EMD Serono, Inc.$42K
  • plus $17K from 2 others

What the payments were for

  • Consulting fees$246,00917%
  • Speaking & faculty fees$1,007,35768%
  • Grants$4,0000%
  • Travel & lodging$154,77211%
  • Food & beverage$56,9754%
  • Education$7810%
  • Charitable contribution$2,0000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,471,894 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$8,893,202
Medicare patients
379
Services billed
702,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Teriflunomide39$152,153
TecfideraDimethyl Fumarate15$139,401
Kesimpta PenOfatumumab12$121,633
ZeposiaOzanimod Hydrochloride13$115,568
Dalfampridine ErDalfampridine98$88,378
VyvanseLisdexamfetamine Dimesylate31$15,332
Modafinil61$6,308
Baclofen132$5,415
Gabapentin119$3,190
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine46$1,372
Zolpidem Tartrate ErZolpidem Tartrate13$1,278
Oxybutynin Chloride ErOxybutynin Chloride41$989
Oxybutynin Chloride39$941
Armodafinil16$910
Pregabalin18$767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$356,871$139,40115 claims
E.r. Squibb & Sons, L.L.C.Zeposia$114,175$115,56813 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$25$15,33231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 neurology providers in Virginia.

Other neurology in Vienna

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →